Why these five U.S. stocks soared over 20% on October 30: Guardant Health to Metsera

In a session marked by selective risk appetite and sharp sector pivots, five U.S.-listed stocks stood out on October 30, 2025, each gaining more than 20 percent on a mix of earnings beats, bullish forward guidance, and takeover speculation. As broader equity markets digested a wave of tech earnings and macro uncertainty, names like Guardant Health, FormFactor, Viavi Solutions, Globalstar, and Metsera broke away from the pack—signaling that investors are rewarding high-conviction catalysts with aggressive momentum buying.

What triggered Guardant Health’s massive 27 percent rally, and what it signals for diagnostics investors

Guardant Health, Inc. (NASDAQ: GH) led the day’s rally with a staggering 27.87 percent jump, closing at USD 92.41 after gaining more than USD 20 in a single trading session. The rally came after the precision oncology company delivered a Q3 2025 earnings beat that exceeded investor expectations on both topline and forward guidance.

Revenue rose nearly 39 percent year-on-year to USD 265.2 million, powered by growth in its clinical testing services and Guardant360 suite. More significantly, Guardant Health raised its full-year revenue guidance to the range of USD 965 million to USD 970 million, compared to the previous midpoint of USD 920 million. This sharp upward revision indicated sustained adoption momentum across its early detection and recurrence monitoring segments.

Analysts responded quickly, with several research firms reaffirming their “Buy” ratings and emphasizing Guardant Health’s growing leadership in the non-invasive cancer diagnostics segment. Institutional sentiment spiked after the results, with options volume and call-buying activity rising sharply.

Guardant Health’s rally is not merely earnings-based. It represents a broader shift in investor appetite toward commercial-stage precision medicine companies that are demonstrating scale, revenue growth, and product stickiness. The company’s expanded reimbursement coverage and ongoing clinical partnerships with leading hospitals have positioned it as a compelling growth story.

Investor forums and retail interest also played a role, with Guardant Health trending on multiple stock discussion platforms.

How did FormFactor benefit from semiconductor tailwinds and technical momentum?

FormFactor, Inc. (NASDAQ: FORM) surged 24.16 percent to end the day at USD 59.25, driven by a combination of earnings outperformance and institutional momentum. The company, a provider of semiconductor test and measurement solutions, reported better-than-expected Q3 results with adjusted EPS of approximately USD 0.33 compared to consensus estimates of USD 0.25.

What turned heads beyond earnings was the company’s technical breakout. Its Relative Strength Rating improved to 87, which often serves as a signal for institutional buying in the technical trading community. The stock hit a 52-week high during the session, attracting volume more than five times its three-month average.

FormFactor’s jump also reflects a broader bullish turn in semiconductor testing and packaging, especially with ramp-ups in AI chip validation and advanced-node testing. With major chipmakers accelerating development cycles for next-generation nodes, suppliers like FormFactor are well-positioned to ride the test capacity wave.

Institutional sentiment around the semiconductor sector has been shifting since early October, and FormFactor’s strong execution made it one of the standout mid-cap gainers of the month.

Why Viavi Solutions’ Q1 guidance gave investors confidence in data center and optical recovery

Viavi Solutions Inc. (NASDAQ: VIAV) posted a 22.32 percent rise to close at USD 17.10 after delivering a surprisingly strong Q1 FY26 outlook. Management projected revenue in the range of USD 360 million to USD 370 million, substantially ahead of consensus expectations closer to USD 302 million. EPS guidance was similarly bullish at USD 0.18 to USD 0.20.

The optics and network testing company is benefiting from renewed demand in data center infrastructure, 5G rollout instrumentation, and hyperscaler-driven optical upgrades. Viavi Solutions had earlier completed a strategic acquisition in the test and measurement space, which is now beginning to contribute meaningfully to its top-line growth.

Analysts noted that Viavi’s growth is not simply cyclical but supported by strong order backlogs and improving margins. The earnings call also referenced increased demand from cloud and AI infrastructure clients, providing thematic momentum that aligned with market sentiment for the day.

Viavi Solutions has historically traded in a narrow valuation band, but this guidance beat brought in institutional buyers, many of whom were looking to rotate into profitable names with exposure to AI infrastructure.

What’s behind Globalstar’s sudden rise—and could a SpaceX deal actually materialize?

Globalstar, Inc. (NYSE American: GSAT) skyrocketed by 22.24 percent to close at USD 50.78 following a Bloomberg report that the company had initiated early-stage talks about a potential sale. Notably, the report mentioned SpaceX as one of the interested parties, although discussions were said to be preliminary.

The satellite and low-Earth orbit connectivity company has seen speculative interest before, largely due to its relationship with Apple Inc. and satellite-based emergency communication features in newer iPhones. However, this round of speculation carried more weight, with reports suggesting that Globalstar could command a valuation north of USD 10 billion.

The strategic rationale for a SpaceX–Globalstar deal lies in spectrum consolidation, dual-mode satellite-cellular use cases, and global coverage expansion. While no formal bid has been made public, the mere suggestion of a mega-deal with SpaceX sent retail and institutional investors into a buying frenzy.

Daily volume more than quadrupled the three-month average, and options trading implied expectations for further volatility. For long-term satellite infrastructure investors, the move reignited interest in the M&A narrative across low-Earth orbit players.

Why Metsera’s obesity drug triggered a bidding war between Novo Nordisk and Pfizer—and what’s at stake

Metsera Inc. (NASDAQ: MTSR) rounded off the top five with a 22.06 percent gain, closing at USD 63.73, after news emerged of a potential takeover battle. The American biotechnology company confirmed receipt of an unsolicited proposal from Novo Nordisk A/S, valuing it at up to USD 9 billion. This followed a previously announced acquisition agreement with Pfizer Inc., worth USD 7.3 billion.

Metsera’s lead drug candidate targets obesity through a novel GLP-1/GIP dual agonist mechanism. The compound has shown promising early-stage clinical data, making it a highly coveted pipeline asset in a sector where Big Pharma is eager to expand its metabolic portfolio.

The Novo Nordisk proposal prompted Metsera’s board to deem the offer “superior,” triggering a short window in which Pfizer may revise its original bid. This bidding war backdrop fueled speculative buying, driving Metsera stock to all-time highs on record volume.

Obesity drug developers have become some of the most watched tickers in 2025, and Metsera’s sharp spike reinforced the narrative that platform-ready assets in this space are commanding premium takeouts.

How are institutional investors interpreting the October 30 rally across these high-momentum names?

Across all five names—Guardant Health, FormFactor, Viavi Solutions, Globalstar, and Metsera—the common denominator was a strong, news-driven event that could shift future cash flow expectations or strategic positioning. Three of the five posted upside earnings or guidance surprises (Guardant, FormFactor, Viavi), while two (Globalstar, Metsera) were powered by M&A speculation and strategic interest.

Institutional flows and sentiment indicators suggest that investors are selectively rewarding small- to mid-cap companies that are executing well and aligned with high-conviction themes—whether AI infrastructure, oncology diagnostics, satellite consolidation, or metabolic disease therapies.

With equity markets entering the final stretch of 2025, the outsized one-day moves may also reflect quarterly window dressing or short covering, especially in stocks with historically high short interest like Globalstar.

However, analysts have cautioned that such explosive gains can quickly retrace without follow-through catalysts. Investors will likely watch how these companies sustain momentum in the weeks ahead through additional disclosures, clinical updates, M&A confirmations, or operational execution.

Key takeaways: what the October 30 top gainers reveal about market momentum, M&A, and sector sentiment

• Guardant Health, Inc. (GH) jumped nearly 28 percent after reporting a strong Q3 2025 beat and raising full-year revenue guidance, highlighting accelerating commercial adoption in liquid biopsy and growing institutional conviction.
• FormFactor, Inc. (FORM) rallied more than 24 percent following an earnings beat and a technical breakout, underscoring renewed demand for semiconductor test equipment tied to AI chip validation cycles.
• Viavi Solutions Inc. (VIAV) rose over 22 percent after issuing Q1 FY26 guidance well above consensus, signalling recovering optical and data center testing demand that is drawing fresh institutional flows.
• Globalstar, Inc. (GSAT) gained roughly 22 percent on reports of early-stage sale talks that mentioned SpaceX as an interested party, illustrating how M&A speculation can rapidly reprice satellite and spectrum assets.
• Metsera Inc. (MTSR) climbed about 22 percent after confirming an unsolicited proposal from Novo Nordisk A/S that competes with Pfizer Inc.’s earlier offer, creating a bidding-war narrative that amplified speculative buying.
• The common thread across these moves was event-driven conviction: earnings beats and guidance upgrades attracted quality buyers, while takeover speculation triggered sharp retail and options activity that amplified intraday volatility.
• Investors should watch for follow-through catalysts—sustained revenue beats, confirmed bids or filings, and margin expansion—because these one-day surges can reverse quickly without durable operational confirmation.